Table 3. Response in LAPC and MPC cohorts.
| LAPC cohort (n=29) | MPC cohort (n=37) | Historical (n=146) | P-valuea | |
|---|---|---|---|---|
|
Response,
n
(%) | ||||
| CR | 0 (0) | 0 (0) | 1 (0.7) | |
| PR | 5 (17.2) | 13 (35.1) | 53 (36.3) | |
| SD | 24 (82.7) | 19 (51.5) | 66 (45.2) | |
| PD | 0 (0) | 5 (13.5) | 26 (17.8) | |
| CR+PR | 5 (17.2) | 13 (35.1) | 54 (37.0) | 0.87b |
| CR+PR+SD | 29 (100) | 32 (86.5) | 120 (82.2) | 0.67b |
a
Comparison between evaluable patients in the MPC cohort and historical control group treated with standard FOLFIRINOX as reported by Conroy et al.
b
P-value is based on Fisher exact test for count.